Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo

Journal of Hepatology

Volumn 34, Issue 1, 2001, Pages 114-122

  Seignères, Béatrice ^a   Aguesse Germon, Stéphanie ^a   Pichoud, Christian ^a   Vuillermoz, Isabelle ^a   Jamard, Catherine ^a   Trépo, Christian ^a   Zoulim, Fabien ^a  

^a INSERM   (France)

Author keywords

Antivirals; Hepatitis B virus; Polymerase mutants; Resistance

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; LAMIVUDINE; VIRUS DNA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; DNA SYNTHESIS; DOSE RESPONSE; DRUG RESISTANCE; DUCK; ENZYME ACTIVITY; HEPATITIS B; HEPATITIS B VIRUS; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; STRUCTURAL GENE; VIREMIA; VIRUS GENOME; VIRUS HEPATITIS; VIRUS MUTANT; VIRUS REPLICATION;

ADENINE; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE; HEPATITIS B VIRUS, DUCK; LAMIVUDINE; MOLECULAR SEQUENCE DATA; MUTATION; PHOSPHONIC ACIDS; RNA-DIRECTED DNA POLYMERASE; TRANSCRIPTION, GENETIC;

EID: 0035136133     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)00074-X     Document Type: Article

References (56)

1. The treatment of chronic viral hepatitis
2. Drug therapy for chronic hepatitis B: Antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy
3. Use of novel b-L(-)-nucleoside analogues for treatment and prevention of chronic hepatitis B virus infection and hepatocellular carcinoma
4. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′thiacytidine and related analogues
5. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-b-L-2′,3′-dideoxy-3′-thyacytidine
6. 2′,3′-dideoxy-b-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo
7. Lamivudine as initial treatment for chronic hepatitis B in the United States
8. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
9. A one year trial of lamivudine for chronic hepatitis B
10. Viral dynamics in hepatitis B virus infection
11. Hepatitis B reactivation after lamivudine
12. Lamivudine therapy for chronic hepatitis B: A six month randomized dose-ranging study
13. Lamivudine therapy of WHV-infected woodchucks
14. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus
15. Lamivudine resistance in immunocompetent chronic hepatitis B: Incidence and patterns
16. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
17. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
18. Identification and characterization of mutations in hepatitis B virus resistant to Lamivudine
19. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
20. Virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
21. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance
22. The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2′-deoxy-3′-thiacytidine and a reduced ability to synthesize viral DNA
23. Virus mutants associated with 3TC and famciclovir administration are replication defective
24. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine ((-)-b-L-2′,3′-dideoxy-3′-thiacytidine) in vitro
25. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
26. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate
27. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
28. Nucleotide sequence of a cloned duck hepatitis B virus genome: Comparison with woodchuck and human hepatitis B virus sequences
29. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase
30. Replication of DHBV genomes with mutations at the sites of initiation of minus- and plus-strand DNA synthesis
31. Inhibitory effect of 2′-fluoro-5-methyl-b-L-arabinofuranosyl-uracyl on duck hepatitis B virus replication
32. Inhibitory effect of penciclovirtriphosphate on duck hepatitis B virus reverse transcription
33. Synthesis of hepadnavirus particles that contain replication-defective duck hepatitis B virus genomes in cultures HuH7 cells
34. Woodchuck hepatitis virus X protein is required for viral replication in vivo
35. Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles
36. Hepadnaviral envelope proteins regulate covalently closed circular DNA amplification
37. Duck hepatitis B virus can tolerate insertion, deletion, and partial frameshift mutation in the distal pre-S region
38. The reverse transcriptase of hepatitis B virus acts a protein primer for viral DNA synthesis
39. Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells
40. Residues critical for duck hepatitis B virus neutralization are involved in host cell interaction
41. Cloned duck hepatitis B virus DNA is infectious in pekin ducks
42. Homologous recombination between hepadnaviral genomes following in vivo DNA transfection: Implications for studies of viral infectivity
43. Characterization of the antiviral effect of 2′,3′-dideoxy-2′,3′didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model
44. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection
45. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme
46. Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase
47. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance
48. Early detection of viral resistance by determination of HBV polymerase mutations in patients treated by lamivudine for chronic hepatitis B
49. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine
50. Evolution of Hepatitis B Virus Polymerase Gene Sequence during Famciclovir Therapy for Chronic Hepatitis B
51. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy
52. The sequential occurence of viral mutations in a liver transplant recipient re-infected with hepatitis B: Hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss
53. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro
54. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues
55. Mutations in hepatitis B DNA polymerase asssociated with resistance to lamivudine do not confer resistance to adefovir in vitro
56. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors